Targeted adjuvant: First Data on Alectinib in Patients with operable ALK plus NSCLC

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases
    Lin, Jessica J.
    Jiang, Ginger Y.
    Joshipura, Nencyben
    Ackil, Jennifer
    Digumarthy, Subba R.
    Rincon, Sandra P.
    Yeap, Beow Y.
    Gainor, Justin F.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (04) : 683 - 690
  • [32] Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients
    Yoshida, T.
    Oya, Y.
    Tanaka, K.
    Junichi, S.
    Yoshitsugu, H.
    Hida, T.
    Yatabe, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S619 - S619
  • [33] Exposure-response analyses of ALK-inhibitors crizotinib and alectinib in NSCLC patients
    Groenland, S. L.
    Geel, D. R.
    Janssen, J. M.
    Beijnen, J. H.
    Burgers, S. A.
    Smit, E. F.
    Huitema, A. D. R.
    Steeghs, N.
    ANNALS OF ONCOLOGY, 2019, 30 : 608 - 608
  • [34] Clinical Outcomes, Long-Term Survival and Toleration With Sequential Therapy of First-Line Crizotinib Followed by Alectinib in ALK plus NSCLC
    Zou, Z.
    Xing, P.
    Hao, X.
    Zhang, C.
    Ma, K.
    Shan, L.
    Song, X.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1091 - S1092
  • [35] Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK plus advanced NSCLC (aNSCLC).
    Kim, Dong-Wan
    Gadgeel, Shirish M.
    Gettinger, Scott N.
    Riely, Gregory J.
    Oxnard, Geoffrey R.
    Mekhail, Tarek
    Schmid, Peter
    Dowlati, Afshin
    Heist, Rebecca Suk
    Wozniak, Antoinette J.
    Hernandez, Genevive
    Sarkar, Indrani
    Mitry, Emmanuel
    Foster, Paul
    O'Hear, Carol
    Spahn, Jessica
    Ou, Sai-Hong Ignatius
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Sustained Response to Crizotinib After Resistance to First-Line Alectinib Treatment in Two Patients With ALK-Rearranged NSCLC
    Zheng, Jing
    Sun, Wenjia
    Chen, Wenhong
    Zhou, Jianying
    Zhou, Jianya
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (09) : E150 - E153
  • [37] Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
    Gandhi, L.
    Gadgeel, S.
    Shaw, A.
    Barlesi, F.
    Crino, L.
    Yang, J. C-H.
    Dingemans, A-M. C.
    Kim, D-W.
    de Marinis, F.
    Schulz, M.
    Liu, S.
    Fish, S.
    Kotb, A.
    Ou, S-H. I.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients.
    Yoshida, Tatsuya
    Oya, Yuko
    Shimizu, Junichi
    Tanaka, Kosuke
    Horio, Yoshitsugu
    Hida, Toyoaki
    Yatabe, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis
    Samaca-Samaca, Daniel
    Prieto-Pinto, Laura
    Perez, Andres Yepes
    Valderrama, Carolina
    Hernandez, Fabian
    LUNG CANCER MANAGEMENT, 2023, 12 (02)
  • [40] BUDGET IMPACT ANALYSIS OF ALECTINIB FOR THE TREATMENT OF PATIENTS WITH UNTREATED ALK-REARRANGED NSCLC IN ITALY
    Bellone, M.
    Pradelli, L.
    Recchia, A.
    Caputo, A.
    Masetti, L.
    VALUE IN HEALTH, 2018, 21 : S28 - S28
12345